Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
FDY
Company Profile
Business description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Contact
308 Cailun Road
Zhangjiang Hi-Tech Park
Pudong
Shanghai201210
CHNT: +86 2158953355
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
899
Stocks News & Analysis
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,552.60 | 77.00 | 0.91% |
| CAC 40 | 7,741.00 | 75.38 | 0.98% |
| DAX 40 | 22,700.58 | 320.39 | 1.43% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,904.14 | 14.19 | -0.14% |
| HKSE | 24,382.47 | 894.85 | -3.54% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 51,515.49 | 1,857.04 | -3.48% |
| NZX 50 Index | 12,899.72 | 90.27 | -0.69% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,365.90 | 82.40 | 0.99% |
| SSE Composite Index | 3,813.28 | 143.77 | -3.63% |